Multiple Sclerosis
Conference Coverage
‘Reassuring data’ for two MS meds in pregnancy
Preterm birth, spontaneous abortions, and major congenital anomalies were rare with anti-CD20 drugs ocrelizumab or natalizumab.
Conference Coverage
Should McDonald criteria include optical nerve lesions?
Researchers come out in favor, with a caveat against misdiagnoses.
Conference Coverage
Stem cell transplantation ‘substantially’ superior to fingolimod in cutting MS relapse risk
AHSCT is substantially superior to fingolimod and marginally superior to natalizumab in reducing the risk of posttreatment relapses.
News
Higher cardiovascular fitness may help preserve mobility in MS
Cardiorespiratory fitness “may exert neuroprotective effects on the central nervous system.”
Conference Coverage
High-efficacy therapies for MS: When and how to use them
Experts make the case for use of high-efficacy therapies in MS.
News
One in three MS patients reports chronic itch
Itch is historically underrecognized as a symptom of MS, but physicians should know that it is common and may negatively impact quality of life....
Expert Perspective
MS Researchers Wonder Aloud: Is Remyelination Possible?
Literature Review
Ublituximab bests teriflunomide in head-to-head clinical trials
The results of the ULTIMATE I and II trials may pave the way for ublituximab’s approval as the third high-efficacy anti-CD20 monoclonal antibody...
Conference Coverage
Cognitive impairment may predict physical disability in MS
Clinicians should consider testing cognitive processing speed in patients with MS to identify those who are at increased risk for disease...
News
COVID vaccination in DMT-treated MS patients: New data